Arvinas (ARVN) EBITDA (2017 - 2026)
Arvinas (ARVN) recorded quarterly EBITDA of -$59.2 million in Q1 2026, up 12.43% quarter-over-quarter from -$67.6 million in Q4 2025, and down 170.98% on a YoY basis from $83.4 million in Q1 2025.
Arvinas (ARVN) EBITDA (2017 - 2026) Analysis & Trends
Arvinas' EBITDA history runs 10 years deep, the most recent figure standing at -$59.2 million for Q1 2026.
- In Q1 2026, EBITDA fell 170.98% year-over-year to -$59.2 million; the TTM figure through Mar 2026 stood at -$223.2 million (down 448.4% YoY), while the FY2025 annual figure was -$80.6 million, up 58.62% from the prior year.
- EBITDA was -$59.2 million for Q1 2026 at Arvinas, up from -$67.6 million in the prior quarter.
- In the past five years, EBITDA ranged from a high of $83.4 million in Q1 2025 to a low of -$148.7 million in Q4 2023.
- Historically, EBITDA has averaged -$57.8 million across 5 years, with a median of -$66.2 million in 2023.
- The sharpest annual moves came in 2025 and 2026: EBITDA soared 217.96% in 2025, then sank 170.98% in 2026.
- A 5-year view of EBITDA shows it stood at -$77.2 million in 2022, then sank by 92.62% to -$148.7 million in 2023, then jumped by 67.59% to -$48.2 million in 2024, then slumped by 40.25% to -$67.6 million in 2025, then rose by 12.43% to -$59.2 million in 2026.
- The last three EBITDA figures came in at -$59.2 million (Q1 2026), -$67.6 million (Q4 2025), and -$34.7 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.92 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -13.63 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -19.70 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.82 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.44 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -752,618.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.14 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -65.83 Mn |
| 10 | Arvinas | 492.16 Mn | -122.74 Mn | - | -59.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -59.20 Mn |
| Dec 31, 2025 | -67.60 Mn |
| Sep 30, 2025 | -34.70 Mn |
| Jun 30, 2025 | -61.70 Mn |
| Mar 31, 2025 | 83.40 Mn |
| Dec 31, 2024 | -48.20 Mn |
| Sep 30, 2024 | -41.30 Mn |
| Jun 30, 2024 | -34.60 Mn |
| Mar 31, 2024 | -70.70 Mn |
| Dec 31, 2023 | -148.70 Mn |
| Sep 30, 2023 | -61.00 Mn |
| Jun 30, 2023 | -66.20 Mn |
| Mar 31, 2023 | -75.30 Mn |
| Dec 31, 2022 | -77.20 Mn |
| Sep 30, 2022 | -69.00 Mn |
| Jun 30, 2022 | -73.30 Mn |
| Mar 31, 2022 | -77.50 Mn |
| Dec 31, 2021 | -57.00 Mn |
| Sep 30, 2021 | -46.90 Mn |
| Jun 30, 2021 | -50.50 Mn |